| FAQ/Help |
| Calendar |
| Search |
| Today's Posts |
12-13-2016, 02:10 AM
|
#1 | ||
|
|||
|
News Gatherer
Community Support Team
|
Seeking Alpha Voyager Therapeutics: Early Efficacy In Parkinson's Merits Investor Interest Seeking Alpha Early data from a phase 1b trial for gene therapy product VY-AADC01 in Parkinson's Disease was promising, though several questions remain unanswered. In addition to dose escalation, management has several options available to potentially increase ... Gene Therapy Shows Early Promise for Treating Parkinson'sR & D Magazine Combined gene-therapy and pharmaceutical treatment for Parkinson's diseasePHG Foundation all 3 news articles » More... |
||
|
 Reply With Quote
|
| Reply |
|
|
Similar Threads
|
||||
| Thread | Forum | |||
| Acadia Faces Education Battle With Parkinson's Drug - Investor's Business Daily | Parkinson's News | |||
| Current Price Targets For Voyager Therapeutics, Inc. (NASDAQ:VYGR) | ALS News & Research | |||
| gene therapy - Voyager Therapeutics Initiates Third Cohort in Ongoing Phase 1b Clini | Parkinson's Disease | |||
| Rapid onset of efficacy of rasagiline in early Parkinson's disease. | Parkinson's Disease | |||
| Cell based therapeutics to treat Parkinson | Parkinson's Disease | |||
Voyager Therapeutics: Early Efficacy In Parkinson's Merits Investor Interest - Seekin
Linear Mode
